Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,409.62
(
1.04%
)
US TECH 100
22,672.20
(
1.53%
)
Dow Jones
45,516.22
(
0.66%
)
Brent Oil
107.53
(
-0.96%
)
Bitcoin
66,611.00
(
-0.17%
)
News Focus
News Focus
Post# of 257318
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122827
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 203896

Monday, 09/12/2016 10:45:43 AM

Monday, September 12, 2016 10:45:43 AM

Post# of 257318
AMRN -10% on REDUCE-IT continuation—i.e. failure to hit first-interim-analysis efficacy threshold for stopping the trial:

http://finance.yahoo.com/news/amarin-reduce-cardiovascular-outcomes-study-090000912.html

The second interim analysis is expected to occur in 1H17.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today